Endocrine Abstracts

Background: Adults with growth hormone deficiency (GHD) have increased central fat deposits, hypertriglyceridemia, and hyperglycaemia, with an increased risk of developing metabolic syndrome and cardiovascular disease, conditions that can lead to a diminished quality of life. This study analyzed comorbidities among adults with GHD in the US who had Medicaid or commercial health insurance.Methods: In this retrospective cohort study using IBM Marketscan Me...

Objectives: Lonapegsomatropin (SKYTROFA; TransCon hGH), a prodrug of somatropin, is approved by the EMA and FDA for once-weekly treatment of pediatric growth hormone deficiency (GHD). Lonapegsomatropin uses TransCon® technology, which combines a parent drug transiently linked to an inert carrier to achieve sustained release. The characterization of anti-drug antibodies (ADAs) was assessed in 3 phase 3 trials of lonapegsomatropin in pediatric GHD.Met...

Background: Adult GHD results from insufficient growth hormone (GH) secretion from the anterior pituitary gland and may represent either a continuation of childhood-onset GHD or GHD acquired during adulthood. Clinically, adult GHD is associated with central adiposity, decreased lean muscle mass, increased fat mass, decreased bone mineral density, and reduced quality of life. Current standard of care consists of GH replacement via daily injections. Lonapegsomatropin (SKYTROFA; ...